Hypothesis

Senescent p21⁺CD86⁺ macrophages release exosomes enriched in specific phospholipids (phosphatidylserine and sphingomyelin‑16:0/24:1) that act as endogenous danger signals. Upon uptake by tissue‑resident fibroblasts and pericytes, these lipids engage TLR2 and TLR4, triggering MyD88‑dependent NF‑κB and MAPK cascades that synergize with TGF‑β/Smad signaling to lock stromal cells into a persistent pro‑fibrotic phenotype. Blocking the lipid exosome transfer or antagonizing TLR2/4 signaling will prevent exosome‑induced fibrosis and ameliorate age‑related organ degeneration.

Mechanistic Rationale

1. Lipid signature of senescent immune exosomes – Prior work shows senescent exosomes carry distinct proteomic and lipidomic profiles ([https://doi.org/10.1101/2024.06.22.600215]). We propose that the enriched phosphatidylserine and a particular sphingomyelin species are not passive cargo but functional ligands that remodel stromal cell signaling.
2. Lipid‑TLR crosstalk – Phosphatidylserine can bind TLR2/TLR4 in apoptotic contexts ([https://pmc.ncbi.nlm.nih.gov/articles/PMC10216928/]), and sphingomyelin derivatives modulate TLR activity ([https://pmc.ncbi.nlm.nih.gov/articles/PMC12220696/]). In senescent exosomes, these lipids likely cluster in lipid rafts, enhancing receptor avidity.
3. Signal integration with TGF‑β – TLR2/4 activation primes fibroblasts for heightened Smad2/3 phosphorylation and nuclear translocation, creating a feed‑forward loop that sustains α‑SMA and collagen I expression even after exosome clearance.
4. Paracrine amplification – Reprogrammed stromal cells themselves secrete exosomes with similar lipid profiles, propagating the fibrotic signal to neighboring tissues, mirroring the immune‑to‑tissue spread described in neuroinflammatory models ([https://pmc.ncbi.nlm.nih.gov/articles/PMC12847281/]).

Testable Predictions

• Prediction 1: Exosomes isolated from sorted p21⁺CD86⁺ macrophages of aged mice will show a ≥2‑fold increase in phosphatidylserine and sphingomyelin‑16:0/24:1 compared with exosomes from young macrophages (lipidomics by LC‑MS).
• Prediction 2: Treating primary human lung fibroblasts with these senescent macrophage exosomes will raise collagen I secretion by ≥70 % and α‑SMA expression; pretreatment with annexin V (to mask phosphatidylserine) or myriocin (to inhibit sphingomyelin synthesis) will abrogate these effects.
• Prediction 3: Fibroblast exposure to senescent exosomes will increase TLR2/4 surface clustering (measured by FRET) and downstream p‑NF‑κB p65 levels; TLR2/4 knockout fibroblasts will fail to exhibit the pro‑fibrotic response.
• Prediction 4: In vivo, systemic administration of recombinant lactadherin (a phosphatidylserine‑binding protein) to aged mice will reduce exosome‑associated lipid signal in serum (ELISA) and lower hydroxyproline content in heart, liver, and kidney by ≥40 % after 8 weeks.
• Prediction 5: Conversely, intravenous injection of synthetic liposomes reconstituted with the senescent exosome lipid signature into young mice will accelerate collagen deposition in multiple organs, mimicking aged phenotype within 4 weeks.

Falsifiability

If any of the above predictions fail—e.g., senescent macrophage exosomes lack the proposed lipid enrichment, or blocking phosphatidylserine/sphingomyelin does not attenuate fibroblast activation—the hypothesis would be refuted. Likewise, if TLR2/4 deficiency does not protect against exosome‑driven fibrosis, the proposed lipid‑TLR axis would be invalid.

Translational Implication

Confirming this mechanism would justify developing lipid‑targeted exosome interventions (e.g., lipid‑scavenging peptides or TLR2/4 antagonists) as upstream senolytics that halt the broadcast of damage from senescent immune cells, potentially slowing multi‑organ aging before downstream damage accumulates.